Chimeric Small Molecules With Immunogenic Moieties for Protein Labeling
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic modalities struggle to effectively target and activate immune cells against cells expressing specific proteins, particularly disease-specific proteins, and are limited by genetic variations in HLA sub-types and protein expression levels.
Innovation Solution
Development of chimeric small molecules comprising a target protein binding moiety and an immunogenic display moiety, connected via linkers and electrophilic reactive groups, which label proteins and induce immune response by MHC display, and optionally using bifunctional immune cell engagers to activate immune cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional therapeutic modalities are used to target immune cells, then immune cell activation is achieved, but the effectiveness is limited by HLA sub-type variations and protein expression levels
Solution Approach 1:
The chimeric small molecule is divided into distinct functional segments: a protein binding moiety (A) that targets the disease-specific protein, a linker (L) that connects the segments, and an immunogenic display moiety (B) that activates immune cells. This segmentation allows each component to perform its specific function independently, with the protein binding moiety targeting the protein regardless of HLA type, and the immunogenic display moiety providing HLA-independent immune activation through alternative mechanisms such as direct T cell engagement or cytokine release.
Solution Approach 2:
The chimeric small molecule acts as an intermediary agent between the disease-specific protein and the immune cell. Instead of relying on HLA presentation to bridge these two components, the chimeric molecule directly connects the protein binding moiety to the immunogenic display moiety, creating a direct activation pathway that bypasses HLA sub-type restrictions and enables reliable immune cell activation across different HLA backgrounds.
2Reliability
If chimeric small molecules are designed with protein binding moieties and immunogenic display moieties, then targeted immune activation is achieved, but the molecular structure becomes more complex
Solution Approach 1:
The chimeric small molecule design incorporates universal components that can be applied across different disease targets. The protein binding moiety (A) can be selected to target various disease-specific proteins, while the immunogenic display moiety (B) and linker (L) remain modular and reusable. This multi-functionality allows the same basic chimeric architecture to achieve targeted immune activation against different proteins without requiring complete molecular redesign, thereby managing complexity through standardized design principles.
Solution Approach 2:
The molecular structure complexity is managed by optimizing key parameters such as linker length, protein binding moiety affinity, and immunogenic display moiety concentration. By adjusting these parameters rather than fundamentally changing the molecular architecture, the design achieves effective targeted activation while maintaining structural manageability. The linker length, for example, can be optimized to ensure proper spatial arrangement of functional groups without creating excessive structural complexity.
3Ease of operation
If the chimeric small molecule uses electrophilic reactive groups for protein labeling, then intracellular targeting is enhanced, but the risk of off-target effects increases
Solution Approach 1:
The electrophilic reactive groups are strategically positioned within the chimeric small molecule at specific locations that correspond to the protein binding site. This local placement ensures that the reactive groups only engage with the intended target protein and its surrounding microenvironment, minimizing off-target effects. The protein binding moiety (A) is designed to concentrate the reactive groups at the precise intracellular location where the disease-specific protein resides, creating a localized chemical environment that reduces non-specific reactions.
Solution Approach 2:
The design incorporates feedback mechanisms through the protein binding moiety that verifies correct target engagement before the electrophilic reactive groups exert their labeling effect. The protein binding moiety acts as a gatekeeper, ensuring that only when the chimeric molecule is correctly positioned at the target protein does the electrophilic reaction occur. This feedback control through selective binding reduces off-target effects by preventing premature or misplaced chemical reactions.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The chimeric small molecules enable targeted immune cell activation against specific proteins, including disease-specific ones, independent of HLA sub-types, with enhanced cell penetration and intracellular targeting capabilities.
Implementation Method 1
the protein binding moiety facilitates labeling of an amino acid of a protein, via the electrophilic reactive group, with the immunogenic display moiety
Implementation Method 2
major histocompatibility complex (MHC) display of a fragment of the protein labeled with the immunogenic display moiety induces an immune response
Data Source
AI summary
Chimeric small molecules comprising an immunogenic display moiety and methods of using the chimeric small molecules to label proteins with the immunogenic display moiety for MHC display on the surface of a cell or to label cell surface proteins with the immunogenic display moiety for display on the surface of a cell, thereby inducing an immune response.